Newbridge Financial Services Group’s Neurocrine Biosciences NBIX Stock Holding History

Newbridge Financial Services Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20	Closed	-$2.3K	–	1165
2024 Q3	$2.3K	Hold	20	–	–	﹤0.01%	556
2024 Q2	$2.75K	Sell	20 -5	-20%	-$686	﹤0.01%	920
2024 Q1	$3.45K	Buy	25 +5	+25%	+$683	﹤0.01%	938
2023 Q4	$2.63K	Sell	20 -45	-69%	-$5.18K	﹤0.01%	947
2023 Q3	$7.31K	Hold	65	–	–	﹤0.01%	883
2023 Q2	$6.13K	Hold	65	–	–	﹤0.01%	974
2023 Q1	$6.58K	Hold	65	–	–	﹤0.01%	1004
2022 Q4	$7.76K	Hold	65	–	–	﹤0.01%	970
2022 Q3	$7K	Hold	65	–	–	﹤0.01%	973
2022 Q2	$6K	Sell	65 -30	-32%	-$2.77K	﹤0.01%	979
2022 Q1	$9K	Hold	95	–	–	﹤0.01%	966
2021 Q4	$8K	Hold	95	–	–	﹤0.01%	969
2021 Q3	$9K	Sell	95 -1	-1%	-$94	0.01%	904
2021 Q2	$9K	Hold	96	–	–	0.01%	1012
2021 Q1	$9K	Buy	96 +46	+92%	+$4.82K	0.01%	921
2020 Q4	$5K	Hold	50	–	–	﹤0.01%	853
2020 Q3	$5K	Buy	+50	New	+$5.78K	﹤0.01%	807

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Newbridge Financial Services Group's NBIX Position: Q4 2024 in Review

Newbridge Financial Services Group sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 20 shares — an estimated $2.3K sold.

Newbridge Financial Services Group first reported a position in NBIX in Q3 2020 and held it in 17 quarters. The position peaked at $9K in Q1 2022. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

Newbridge Financial Services Group reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
Newbridge Financial Services Group sold 20 Neurocrine Biosciences shares in Q4 2024, an estimated $2.3K.
Newbridge Financial Services Group first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 17 quarters.
Newbridge Financial Services Group's Neurocrine Biosciences position peaked at $9K in Q1 2022.
600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Newbridge Financial Services Group's 13F filing for Q4 2024, filed 28 Jan 2025.